Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Will paying patients to take oral antipsychotics boost adherence?

Publish date:: November 15, 2019

Key clinical point: Economic incentives improve adherence to long-acting injectable antipsychotics.

Major finding: Modest payments to patients as a reward for taking their long-acting injectable antipsychotic agents improve medication adherence by 12%-15%.

Study details: This was an analysis of four published studies.

Disclosures: The presenter reported having no financial conflicts of interest.

Citation:

REPORTING FROM ECNP 2019

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Schizophrenia & Other Psychotic Disorders

Risk factors for QTc prolongation during amisulpride therapy in schizophrenia,

Schizophrenia: Reinitiating clozapine can be considered in patients who have previously discontinued it,

Elevated IL-18 levels in patients with schizophrenia,

Schizophrenia: Antipsychotic choice may influence driving-related cognitive performance,

Treatment-resistant schizophrenia: Is slower-than-recommended titration of clozapine beneficial?,